Skip to main content
CTKB
NASDAQ Industrial Applications And Services

Cytek Hit With $56.1M Patent Verdict in Beckman Coulter Case

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$4.56
Mkt Cap
$625.219M
52W Low
$3.28
52W High
$6.18
52W Position info
39% above low
Off High info
26% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CTKB sits 39% above its 52-week low of $3.28.

Summary

Jury awards Beckman Coulter $56.11M in damages against Cytek in patent case; Cytek won on 3 of 4 claims and will appeal the remaining finding.


Key Events · Legal and Risk Events · CTKB

  • Jury Verdict in Patent Case

    A Delaware jury found Cytek infringed one Beckman Coulter patent claim under the doctrine of equivalents, while finding noninfringement and invalidity on the other three asserted claims.

  • Damages Award

    The jury awarded $20 million in lost profits and $36.11 million in royalties, totaling approximately $56.11 million in past damages.

  • Appeal Planned

    Cytek intends to pursue post-verdict motions challenging the infringement finding and damages award, and may appeal to the U.S. Court of Appeals for the Federal Circuit.

  • No Product Impact

    The verdict does not require changes to Cytek's current product offerings or operations; spectral flow cytometry products remain available worldwide.


Analysis · CTKB · Industrial Applications And Services

A Delaware jury found Cytek infringed one Beckman Coulter patent claim under the doctrine of equivalents, awarding $56.11 million in damages — $20 million in lost profits plus $36.11 million in royalties. That's a material hit for a company with a $625 million market cap and a widening net loss of $12.2 million last quarter. Cytek won on three of four claims, so its core Full Spectrum Profiling products remain on the market, but the damages award alone exceeds a full quarter of revenue. The company plans post-verdict motions and a possible Federal Circuit appeal, which could take years and add legal costs. The verdict does not force product changes, but the financial exposure and ongoing litigation overhang are significant.

How filings like this one have moved

In the 30 days to Aug 24, 2026, 44% of the 972 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CTKB was trading at $4.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $625.2M. The 52-week trading range was $3.28 to $6.18. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CTKB - Latest Insights

CTKB
Aug 05, 2026, 5:10 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.20
Real-time Price: $4.56 info
Change: +$0.360 (+9%) info
Market Cap: $625.219M info
CTKB
Aug 05, 2026, 5:06 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $4.56 info
Change: +$0.5227 (+13%) info
Market Cap: $625.219M info
CTKB
Aug 05, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.20
Real-time Price: $4.56 info
Change: +$0.360 (+9%) info
Market Cap: $625.219M info
CTKB
Jun 02, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.19
Real-time Price: $4.56 info
Change: +$0.370 (+9%) info
Market Cap: $625.219M info
CTKB
Jun 02, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.19
Real-time Price: $4.56 info
Change: +$0.370 (+9%) info
Market Cap: $625.219M info